Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

Nature Clinical Practice Oncology

Volumn 5, Issue 9, 2008, Pages 506-507

  Schurko, Brian ^a   Oh, William K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PAIN; CASTRATION; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG RESPONSE; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT DURATION;

EID: 51149085584     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1201     Document Type: Article

References (7)

1. American Cancer Society. Cancer facts & figures 2007. [http://www.cancer.org/docroot/STT/stt_0_2007.asp?sitearea= STT&level=1] (accessed 23 April 2008)
2. Food and Drug Administration (online 19 May 2004) FDA approves new indication for taxotere - prostate cancer. [http://www.fda.gov/bbs/ topics/news/2004/NEW01068.html] (accessed 3 June 2008)
3. Food and Drug Administration (online 13 November 1996) FDA approves new drug for treating prostate cancer. [http://www.fda.gov/bbs/topics/ ANSWERS/ANS00771.html] (accessed 3 June 2008)
4. Osoba D et al. (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17, 1654-1663
5. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 1502-1512
6. Petrylak DP et al. (2004) Docetaxel and estramustine compared with, mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
7. Berthold DR et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in ihe TAX 327 study. J Clin Oncol 26: 242-245